Related Experiment Video
Updated: Jun 21, 2026

12:55
P50 Sensory Gating in Infants
Published on: December 26, 2013
Sensorimotor gating in neurotensin-1 receptor null mice
D Feifel1, Z Pang, P D Shilling
1Department of Psychiatry, University of California, San Diego, Medical Center, 200 West Arbor Drive, San Diego, CA 92103-8218, USA. dfeifel@ucsd.edu
Neuropharmacology
|July 15, 2009
Summary
Endogenous neurotensin (NT) does not regulate baseline prepulse inhibition (PPI) or its disruption by amphetamine/dizocilpine via NT1 receptors. However, NT1 receptor agonists show antipsychotic potential by enhancing PPI.
Area of Science:
- Neuroscience
- Psychopharmacology
- Genetics
Background:
- Endogenous neurotensin (NT) is implicated in schizophrenia pathophysiology.
- Prepulse inhibition of the startle reflex (PPI) is a key measure of sensorimotor gating relevant to psychosis.
- NT1 receptors are hypothesized to mediate NT's effects on PPI deficits.
Purpose of the Study:
- To investigate the role of NT1 receptors in regulating PPI.
- To assess baseline PPI in wildtype (WT) and NT1 knockout (KO) mice.
- To examine the effects of amphetamine, dizocilpine, and the NT1 agonist PD149163 on PPI in WT and NT1 KO mice.
Main Methods:
- Measured baseline PPI and acoustic startle response in WT and NT1 KO mice.
- Administered intraperitoneal saline, amphetamine, dizocilpine, or PD149163 at various doses.
- Assessed PPI and startle response after drug administration on separate test days.
Main Results:
- No significant differences in baseline PPI or startle response between WT and NT1 KO mice.
- Both genotypes showed similar PPI disruption by dizocilpine and amphetamine.
- PD149163 significantly increased PPI and decreased startle in WT mice, but not in NT1 KO mice.
Conclusions:
- Endogenous NT acting at NT1 receptors does not regulate baseline PPI or its disruption by amphetamine/dizocilpine.
- Pharmacological activation of NT1 receptors with agonists shows potential for antipsychotic effects.
- NT1 receptor agonists may be a viable therapeutic strategy for psychosis-related sensorimotor gating deficits.

